Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
UNAIDS/WHO Working Group on Global HIV/AIDS and STD Surveillance. Report on the Global HIV/AIDS Epidemic. Ginebra: World Health Organization, 2002. Disponible en: http://www.unaids.org.
[2.]
J.T. Ramos, J. Saavedra Lozano, M.I. De José.
Tratamiento de la infección por VIH en la infancia.
An Esp Ped, 99 (1998), pp. 222-237
[3.]
J.A. Iribarren, J.T. Ramos, L. Guerra, O. Coll, P. Domingo, M.I. De José, et al.
Prevención de la transmisión vertical y tratamiento de la infección por el virus de la inmunodeficiencia humana en la mujer embarazada.
Enf Inf Microb Clin, 19 (2001), pp. 314-335
[4.]
M. Sharland, G. Castelli, J.T. Ramos, S. Blanche, D. Gibb.
on behalf of the PENTA steering committee. PENTA (Pediatric European Network for Treatment of AIDS). European guidelines of antiretroviral treatment of HIV-infected children.
HIV Medicine, 3 (2002), pp. 215-226
[5.]
S. Gortmaker, M. Hughes, R. Oyomopito, M. Brady, G.M. Johnson, G.R. Seage, et al.
Impact of introduction of protease inhibitor therapy on reductions in mortality among children and youth infected with HIV-1.
N Engl J Med, 345 (2001), pp. 1522-1528
[6.]
F.T. Saulsbury.
Resolution of organ specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy.
Clin Infect Dis, 32 (2001), pp. 464-468
[7.]
M.M. De Martino, P.A. Tovo, M. Balducci, L. Galli, C. Gabiano, G. Rezza, et al.
Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection.
Jama, 284 (2000), pp. 190-197
[8.]
J. Sánchez-Granados, J.T. Ramos, P. Rojo, M.I. González-Tomé, S. Fernández de Miguel, P. Ferrando, et al.
Impact of HAART on the survival and disease progression in HIV-1 infected children.
Pediatr Infect Dis J, 22 (2003), pp. 863-867
[9.]
D.M. Gibb, A. Newberry, N. Klein, A. De Rossi, I. Grosch-Woerner, A. Babiker.
Immune repopulation after HAART in previously untreated HIVinfected children.
Lancet, 355 (2000), pp. 1331-1332
[10.]
J.T. Ramos, J. Beceiro, C. Calvo, L. Ciria, M.I. De José, M.J. Mellado, et al.
Effect of HARRT on CD4 and viral load in HIV-1 infected children: a crosssectional study.
2nd International AIDS Society Congress [abstract 1087]. París, (2003),
[11.]
R.B. Van Dike, S. Lee, G.M. Jonhson, A. Wiznia, K. Mohan, K. Stanley, et al.
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Pediatrics, 109 (2002), pp. e6
[12.]
D.M. Gibb, R.L. Goodall, V. Giacomet, L. McGee, A. Compagnucci.
Lyall H for the PENTA Steering Committee. Adherence to prescribed antiretroviral therapy in with human immunodeficiency virus infected children.
Pediatr Infect Dis J, 22 (2003), pp. 56-62
[13.]
E.G. Leonard, G.A. McComsey.
Metabolic complications of antiretroviral therapy in children.
Pediatr Infect Dis J, 22 (2003), pp. 77-84
[14.]
J.T. Ramos, L. Garcia, P. Rojo, C. Ruano, J. Ruiz Contreras, F. Hawkins.
High prevalence of metabolic abnormalities in HIV-infected children treated with HAART.
10th Conference on Retroviruses and Opportunistic infections [abstract 772]. Boston, (2003),
[15.]
J.A. Church, W.G. Mitchell, I. González-Gómez, J. Christensen, T.H. Vu, S. Dimauro, et al.
Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver filure in a HIV-infected child treated with combination antirretroviral therapy.
J Pediatr, 138 (2001), pp. 748-751
[16.]
S. Arpadi, P. Cuff, M. Horlick, J. Wang, D.P. Kotler.
Lypodystrophy in HIV-infected children is associated with high viral load and low CD4-lymphocyte count and CD4-lymphocyte percentage and baseline and use of protease inhibitors and stavudine.
J Acquir Immun Def Syndr, 27 (2001), pp. 30-34
[17.]
P. Brambilla, D. Bricalli, N. Sala, F. Renzetti, P. Manzoni, A. Vanzulli, et al.
Highly active antiretroviraltreated HIV-infected children show fat distribution changes even in the absence of clinical evidence of lipodystrophy.
Aids, 15 (2001), pp. 2415-2422
[18.]
S. Arpadi, M. Horlick, J. Thornton, P.A. Cuff, J. Wang, D.P. Kotler.
Bone mineral content is lower in prepubertal HIV-infected children.
J Acquir Immune Def Syndr, 29 (2002), pp. 450-454
[19.]
M. Schambelan, C.A. Benson, A. Carr, J.S. Currier, M.P. Dubé, J.G. Gerber, et al.
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
J Acquir Immune Defic Syndr, 31 (2002), pp. 257-275
[20.]
D.M. Gaughan, L.M. Mofenson, M.D. Hughes, S. Seage.
Oleske J for the PACTG 219 Team. Avascular necrosis of the hip (Leggs-Calve-perthes disease) in HIV-infected children in long-term followup: PACTG Study 219.
Pediatrics, 109 (2002), pp. 1-8
[21.]
K. Miller, H. Masur, E.C. Jones, G.E. Joe, M.E. Rick, G.G. Kelly, et al.
High prevalence of osteonecrosis of the femoral head in HIV-infected adults.
Ann Intern Med, 137 (2002), pp. 17-24
[22.]
P. Yeni, S. Hammer, C. Carpenter, D.A. Cooper, M.A. Fischl, J.M. Gatell, et al.
Antiretroviral treatment for adult with HIV infecction in 2002: updated recommendations of the IAS-USA Panel.
Jama, 288 (2002), pp. 222-235
[23.]
Guidelines for the use of antiretroviral agents in pediatric HIV infection [consultado en noviembre de 2001]. Disponible en: http://www.hivatis.org
[24.]
L.M. Mofenson, J. Korelitz, W.A. Meyer, J. Bethel, K. Rich, S. Pahwa, et al.
The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children.
J Infect Dis, 175 (1997), pp. 1029-1038
[25.]
T. Duong.
on behalf of HIV Paediatric Prognostic Markers Collaborative Study Group. Predictive value of CD4 count and viral load for disease progression in untreated HIV-infected children [en prensa].
Lancet, (2003),
[26.]
M.I. De José, J.T. Ramos, S. Álvarez, M.A. Muñoz-Fernández.
Vertical transmission of HIV-1 variants to reverse transcriptase and protease inhibitors.
Arch Intern Med, 161 (2001), pp. 2738-2739
[27.]
Pediatric European Network for treatment of Aids.
A randomized trial evaluating 3 NRTI regimens with and without nelfinavir in previously untreted HIV-infected children: 48 week follow-up from the PENTA 5 trial.
Lancet, 359 (2002), pp. 733-740
[28.]
X. Sáez-Llorens, A. Violari, C.O. Deetz, R. Rode, P. Gómez, E. Handelsman, et al.
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus infected children.
Pediatr Infect Dis J, 22 (2003), pp. 216-223
[29.]
S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, et al.
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
N Engl J Med., 346 (2002), pp. 2039-2046
[30.]
J. Durant, P. Clevenberg, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, et al.
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.
Lancet, 353 (1999), pp. 2195-2199
[31.]
E. Mc Farland, D. Johnson, T. Fenton, P. Muresan, J. McNamara, E. Hawkins, et al.
A phase I/II study of the safety and immunogenicity of an HIV-1 ALVAC vaccine in infants born to HIV-infected mothers.
10th Conference on Retroviruses and Opportunistic infections [abstract 99]. Boston, (2003),
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados